2nd Circ. Hands GSK A Win In Avandia Securities Suit

A federal appeals court has shot down an appeal from a group of investors who claimed GlaxoSmithKline PLC violated securities laws by concealing the potential cardiovascular risks of its blockbuster diabetes...

Already a subscriber? Click here to view full article